- Home
- DTF vs ALXO Comparison
DTF vs ALXO Comparison
Compare DTF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | ALXO |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 68.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DTF | ALXO |
|---|---|---|
| Price | $11.47 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 21.1K | ★ 346.6K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.29 | $0.40 |
| 52 Week High | $11.19 | $2.27 |
Technical Indicators
Market Signals| Indicator | DTF | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 63.27 |
| Support Level | $11.41 | $1.36 |
| Resistance Level | $11.46 | $1.93 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 72.56 | 72.08 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.